Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
First Claim
1. A method of inhibiting binding of Endokine-alpha to endogenous Endokine-alpha receptors in a mammal comprising administering to said mammal an effective amount of TR11 polypeptide selected from the group consisting of:
- (a) a polypeptide whose amino acid sequence comprises amino acid residues −
25-137 of SEQ ID NO;
2;
(b) a polypeptide whose amino acid sequence comprises amino acid residues 1-137 of SEQ ID NO;
2;
(c) a polypeptide whose amino acid sequence comprises amino acid residues 1-114 SEQ ID NO;
2; and
(d) a polypeptide fragment of the polypeptide of SEQ ID NO;
2, wherein said fragment binds endokine-alpha;
in a pharmaceutically acceptable carrier.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding human TR11, TR11SV1, and TR11SV2 receptors. TR11, TR11SV1, and TR11SV2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR11, TR11SV1, and TR11SV2 receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR11, TR11SV1, and TR11SV2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR11, TR11SV1, and TR11SV2 receptors.
-
Citations
28 Claims
-
1. A method of inhibiting binding of Endokine-alpha to endogenous Endokine-alpha receptors in a mammal comprising administering to said mammal an effective amount of TR11 polypeptide selected from the group consisting of:
-
(a) a polypeptide whose amino acid sequence comprises amino acid residues −
25-137 of SEQ ID NO;
2;
(b) a polypeptide whose amino acid sequence comprises amino acid residues 1-137 of SEQ ID NO;
2;
(c) a polypeptide whose amino acid sequence comprises amino acid residues 1-114 SEQ ID NO;
2; and
(d) a polypeptide fragment of the polypeptide of SEQ ID NO;
2, wherein said fragment binds endokine-alpha;
in a pharmaceutically acceptable carrier. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
-
-
15. A method of inhibition binding of Endokine-alpha to endogenous Endokine-alpha receptors in a mammal comprising administering to said mammal an effective amount of TR11 polypeptide selected from the group consisting of:
-
(a) a polypeptide whose amino acid sequence comprises the signal sequence and the extracellular domain of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209341;
(b) a polypeptide whose amino acid sequence comprises the extracellular domain of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209341; and
(c) a polypeptide fragment of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209341;
wherein said fragment binds endokine-alpha;
in a pharmaceutically acceptable carrier. - View Dependent Claims (16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)
-
Specification